Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece

BACKGROUND: Multiple myeloma is a hematologic malignancy that incurs a substantial economic burden in care management. Since most patients with multiple myeloma eventually relapse or become refractory to current therapies (rrMM), the aim of this study was to assess the cost-effectiveness of the comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Fragoulakis, V, Kastritis, E, Psaltopoulou, T, Maniadakis, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627436/
https://www.ncbi.nlm.nih.gov/pubmed/23596356
http://dx.doi.org/10.2147/CMAR.S43373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627436/
https://www.ncbi.nlm.nih.gov/pubmed/23596356
http://dx.doi.org/10.2147/CMAR.S43373

Ejemplares similares